

Investor Presentation

FY 2006 Financial Results



The specialist in psychiatry
and pioneer in neurology



Safe Harbour Statement

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.



Lundbeck is an international pharmaceutical company specializing in central nervous system disorders


Facts on Lundbeck:

- **Founded by Hans Lundbeck in 1915**
- **An integrated company with core competencies in research, development, production, marketing and sales**
- **International presence with pharmaceuticals in more than 90 markets**
- **Marketed pharmaceuticals to treat Alzheimer's disease, depression, anxiety, Parkinson's disease and schizophrenia**
- **Headquarters in Copenhagen, Denmark**
- **Approximately 5,000 employees**



CNS: world's biggest niche (17% of world pharmaceutical sales)...

2005 CNS market
USDbn 93.8 (+5%)



Lundbeck focus

Depression, N6A

Psychosis, N5A

Alzheimer's disease, N7D

Parkinson's disease, N4A

Sleep disorders, N5B

Alcohol dependence, N7X

Stroke, B1D

USDbn 0.7 (+1%)

Source: IMS world review 2006



... and Lundbeck holds a broad CNS portfolio of current products and projects in late-stage development

| | <u>Launched products</u> | <u>Late-stage pipeline</u> |
|--------------------------|---|---|
| Depression, N6A | Cipralex [®] , 2002 / Lexapro [®] , 2002 (US partner, Forest Labs.) | Lu AA 21004, phase II |
| Psychosis, N5A | Serdolect [®] , 2006 | Bifeprunox (Solvay), phase III Lu 31-130, phase II |
| Alzheimer's disease, N7D | Ebixa [®] (Merz), 2002 | |
| Parkinson's disease, N4A | Azilect [®] (Teva), 2005 | |
| Sleep disorders, N5B | | Gaboxadol, phase III (US partner, Merck) |
| Alcohol dependence, N7X | | Nalmefene (BioTie), phase III |
| Stroke, B1D | | Desmoteplase (PAION), phase III |





2006 Achievements

- **Double digit revenue growth in own markets**
 - Cipralex[®] (+34%) and Ebixa[®] (+23%) sales
- **Pipeline progression and new licensing candidate**
- **Azilect and Serdolect rolled out in Lundbeck markets**
 - Both launched in several markets
- **Forest inventory reduction completed**
 - From inventory of 16 months sales to approximately 9 months
 - Lexapro income to reflect underlying market growth in 2007
- **Positive outcome of Lexapro trial in the US**
- **Improved Cipralex profile**
 - OCD, head-to-head study vs. Cymbalta[®] & Paxil[®]
- **LifeCycle Pharma IPO**



Financial figures FY 2006



| DKKm | 2006 | Guidance 2006 |
|-----------------------------|-------|-----------------------|
| Revenue | 9,221 | |
| R&D (21.2% of revenue) | 1,958 | |
| EBIT | 1,784 | |
| EBIT margin | 19.3% | |
| EBIT, excl. one time items* | 1,629 | Appr. DKK 1.6 billion |

* Gain of DKK 155 million from IPO of LCP in Q4 2006.



Optimizing efforts in Europe and expansion in US and Asia

USA

RESEARCH

Located in NJ – Focusing on depression and anxiety

SALES

Commercial HQ established in Philadelphia, PA

CNS specialist sales force to be established supporting the potential launch of gaboxadol, sertindole and other future compounds

Europe

RESEARCH

Located in Denmark – Focusing on psychiatric and neurological diseases

SALES

Fully fledged CNS sales infrastructure

Japan

DEVELOPMENT

Late stage development program with gaboxadol, escitalopram and desmoteplase

SALES

CNS sales infrastructure to be established

Currently four late stage drug candidates in Japan

Branded market position - Lundbeck's three leading compounds

Cipralex®/Lexapro®

USA

#1 in volume (Dec 06)
#2 in value (Dec 06)

Europe

#1 in volume (Dec 06)
#2 in value (Dec 06)

International Markets*

#3 in volume (Q4 06)
#3 in value (Q4 06)

Ebixa® (memantine)**

Europe

#2 in volume (Dec 06)
#2 in value (Dec 06)

International Markets*

#3 in volume (Q4 06)
#4 in value (Q4 06)

Azilect® (launch 2005)

Europe

#11 in volume (Dec 06)
#6 in value (Dec 06)

* International markets are all markets outside USA and Europe.

** Compound market share

Source: IMS Health December & Q4 2006, retail only




Cipralex® / Lexapro® - growth in market share as well as underlying market growth

Antidepressant market


Europe

Market share, value – market growth, volume



USA

Market share, value – market growth, volume



- Market volume growth (3 months average)
- Cipralex®
- Combined
- Citalopram


- Market volume growth (3 months average)
- Lexapro®
- Combined
- Citalopram



Ebixa® - Lundbecks second largest product

Anti-alzheimers market shares

Europe



Source: IMS Health, December 2006


- Ebixa® available for patients diagnosed with moderate to severe Alzheimers Disease
- Memantine is the second most prescribed antialzheimer compound in Europe



Azilect® - launched in more than 20 countries

Anti-parkinsons market shares

Europe




- Lundbeck has launched Azilect® in more than 20 countries
- Once daily treatment
- Approved for monotherapy and adjunct therapy with levodopa treatment



Launch of new compound – Serdolect®

Value conversion

Europe – antipsychotic market in volume



Source: IMS Health, December 2006 & Lundbeck market research

- Value conversion driving growth in European market
- Launched in 14 countries in 2006
- Expected launch in approximately 20 countries in 2007
- Serdolect® is developed by Lundbeck and the company holds world-wide rights



Financial guidance and significant news flow

Financial guidance

| 2006 actual | | 2007 guidance |
|-------------------|-------------|----------------------------|
| DKK 1,784 million | EBIT | More than DKK 2.5 billion* |
| 19.3% | EBIT margin | 25%* |
| DKK 762 million | Capex | DKK 650 million |

* Exclusive potential milestone payment of USD 75 million from Merck & Co.

Significant news flow

Gaboxadol

- Phase III data presented at APA (May 2007) and APSS (June 2007)
- Filing with FDA mid 2007

Desmoteplase

- Phase III headline data (DIAS-2) to be announced mid 2007

Lu AA21004










- Phase II data to be announced by the end of 2007

New drug candidates

- Expected 2-3 new candidates entering clinical phase I



Pharmaceuticals in clinical development

| Indication Compound | Activity | Development step | | | Registration application | Expected launch |
|---------------------------------|--|--|---|---|-----------------------------|--------------------|
| | | Phase I | Phase II | Phase III | | |
| Insomnia Gaboxadol | Selective Extra-synaptic GABA agonist | | |  | 2007 | 2008 |
| Schizophrenia Bifeprunox | Dopamin/ serotonin | | |  | 2009+ | |
| Stroke Desmoteplase | Plasminogen activator | | |  | 2009+ | |
| Alcohol dependence Nalmefene | Specific opioid receptor antagonist | | |  | -- | |
| Depression Lu AA21004 | Serotonin Modulator & Stimulator | |  | | 2009+ | |
| Psychosis Lu 31-130 | Monoaminergic | |  | | 2009+ | |
| Depression Lu AA24530 | Multiple target |  | | | 2009+ | |
| Depression Lu AA34893 | Multiple target |  | | | 2009+ | |
| Mood Disorders Lu AA44608 | Selective NPY receptor antagonist |  | | | 2009+ | |

Late stage pipeline

– Gaboxadol (phase III) for the treatment of insomnia

- Gaboxadol is the first in a new class of treatments for sleep disorders
- Outlicensed to Merck on co-development and co-promoting terms in the US and in Japan

Strategic fit:

- Expansion within CNS
- Access to US and Japan with own sales force


Clinical programme

- Programme is comprised of more than 5,500 people
- US filing mid 2007

In addition

- Selective Extrasynaptic GABAA Agonist (SEGA) –does not interact with the benzodiazepine binding site
- Improved sleep quality
- Increased slow-wave sleep without suppressing REM sleep

Prevalence in US:
+60 mio people



Source: Decision Resources, COGNOS, August 2004



Late stage pipeline – Bifeprunox (phase III) for the treatment of schizophrenia

- Bifeprunox is a latest generation atypical antipsychotic
- Inlicensed from Solvay in Belgium and is jointly developed with Solvay and Wyeth (North American rights)

Strategic fit:

- Fits well into Lundbeck's position within antipsychotics
- Leverage on existing European specialist sales force

Clinical programme

- Phase III has so far included more than 2,600 patients
- Additional comparative clinical work will be conducted for European filing

In addition

- D2 and 5-HT1A partial agonist
- Results of the current clinical programme:
 - Significant antipsychotic activity compared to placebo
 - Generally well tolerated




Late stage pipeline - Desmoteplase (phase III) for the treatment of ischaemic stroke

- Potentially first compound to treat patients within an up to 9 hours treatment window
- Inlicensed from PAION, Germany
- Lundbeck holds world wide rights excluding USA and Canada

Strategic fit:


- Highly innovative compound
- Administered by neurologists

Disease management



Source: American Heart Association

Prevalence



Source: Decision Resources, COGNOS, February 2004

In addition

- Desmoteplase is a novel plasminogen activator, or blood-clot dissolving agent
- Limit the often fatal consequences of ischaemic stroke



Late stage pipeline

- Nalmefene for the treatment of alcohol dependence

- Potentially new treatment paradigm
- Inlicensed from BioTie, Finland
- Lundbeck holds world wide rights excluding North America, Mexico, UK, Ireland, Turkey, and South-Korea
- Awaiting feed back from authorities regarding regulatory filing requirements

Strategic fit:

- Leverage on existing European GP and specialist sales force
- Co-morbidity to other psychiatric disorders

Prevalence

Estimated 5-6% of population suffers from alcohol abuse or heavy drinking

In addition

Opioid receptor antagonist for the treatment of substance abuse disorders and impulse control disorders



Appendix



The specialist in psychiatry
and pioneer in neurology



More information please contact Investor Relations



Steen Juul Jensen
VP Corporate Finance

Tel: + 45 36 43 30 06
Fax: + 45 36 43 82 62
sjj@lundbeck.com



Jacob Tolstrup
Investor Relations Manager,
North America

Tel: + 1 201 350 0187
Fax: + 1 201 261 0623
jtl@lundbeck.com



Mads Bjerregaard
Investor Relations Officer

Tel: + 45 36 43 41 04
Fax: + 45 36 43 82 62
mbp@lundbeck.com



Lundbeck share

Share information:

- Free float (approximately 62m shares) is traded 2+ times over annually (daily trade of approximately 0.7m)


Trading code:

- Reuters (LUN.CO) / Bloomberg (LUN DC)
- ISIN Number DK0010287234
- Unsponsored ADR programme with Bank of New York CUSIP 40422M107


Index examples:

- End of 2006 weight of 4.0% in OMXC20
- Member of FTSE4Good

Ownership, total outstanding



Ownership, of free float



Revenue – by product / by region

| DKKm | Total | | Europe | | USA | | International Markets | |
|-----------------------|---------------|-------|---------------|-------|-------------|-------|-----------------------|-------|
| | 2006 | 2005 | 2006 | 2005 | 2006 | 2005 | 2006 | 2005 |
| Total revenue | 9,221 | 9,070 | 5,537 | 5,076 | 1,930 | 2,618 | 1,379 | 1,143 |
| <i>Growth</i> | <i>2%</i> | | <i>9%</i> | | <i>-26%</i> | | <i>21%</i> | |
| Cipralex® | 3,508 | 2,625 | 2,766 | 2,131 | - | - | 743 | 494 |
| <i>Growth</i> | <i>34%</i> | | <i>30%</i> | | | | <i>50%</i> | |
| Lexapro® | 1,923 | 2,552 | - | - | 1,923 | 2,552 | - | - |
| <i>Growth</i> | <i>-25%</i> | | | | <i>-25%</i> | | | |
| Ebixa® | 1,361 | 1,105 | 1,214 | 1,003 | - | - | 147 | 102 |
| <i>Growth</i> | <i>23%</i> | | <i>21%</i> | | | | <i>44%</i> | |
| Azilect® | 71 | 6 | 71 | 6 | - | - | - | - |
| <i>Growth</i> | <i>1,068%</i> | | <i>1,068%</i> | | | | | |
| Serdolect® | 10 | - | 10 | - | - | - | - | - |
| <i>Growth</i> | <i>Nm.</i> | | <i>Nm.</i> | | | | | |
| Other pharmaceuticals | 1,973 | 2,550 | 1,476 | 1,936 | 7 | 66 | 489 | 547 |
| <i>Growth</i> | <i>-23%</i> | | <i>-24%</i> | | <i>-89%</i> | | <i>-11%</i> | |
| Other revenue | 375 | 232 | - | - | - | - | - | - |
| <i>Growth</i> | <i>61%</i> | | | | | | | |

Revenue, 5 year figures

| | Revenue, DKK million | | | | | Growth, % | | | |
|------------------------|----------------------|-------|-------|-------|-------|-----------|------|------|--------|
| | 2002 | 2003 | 2004 | 2005 | 2006 | 2003 | 2004 | 2005 | 2006 |
| Total revenue | 9,488 | 9,941 | 9,733 | 9,070 | 9,221 | 5% | -2% | -7% | 2% |
| Cipralex® | 78 | 645 | 1,661 | 2,625 | 3,508 | 729% | 157% | 58% | 34% |
| Lexapro® | 777 | 1,928 | 2,420 | 2,552 | 1,923 | 148% | 26% | 5% | -25% |
| Ebixa® | 29 | 286 | 722 | 1,105 | 1,361 | 893% | 153% | 53% | 23% |
| Azilect® | - | - | - | 6 | 71 | - | - | - | 1,068% |
| Serdolect® | - | - | - | - | 10 | - | - | - | - |
| Other pharmaceuticals* | 8382 | 6,818 | 4,299 | 2,550 | 1,973 | -19% | -37% | -41% | -23% |
| Other revenue | 222 | 264 | 631 | 232 | 375 | 18% | 139% | -63% | 61% |

* Old antipsychotics, antidepressants, incl. citalopram



Revenue, quartely figures

| | Revenue, DKK million | | | | Growth, Y/Y, % | | | |
|--------------------------|----------------------|------------|------------|------------|----------------|------------|------------|------------|
| | Q1 2006 | Q2 2006 | Q3 2006 | Q4 2006 | Q1 2006 | Q2 2006 | Q3 2006 | Q4 2006 |
| Total revenue | 2,232 | 2,198 | 2,248 | 2,543 | 1% | -4% | -1% | 10% |
| Cipralex® | 837 | 856 | 878 | 937 | 57% | 31% | 27% | 26% |
| Lexapro® | 484 | 435 | 479 | 525 | -27% | -34% | -21% | -16% |
| Ebixa® | 311 | 337 | 339 | 374 | 29% | 27% | 16% | 22% |
| Azilect® | 8 | 17 | 19 | 28 | - | - | 954% | 578% |
| Serdolect® | 1 | 2 | 3 | 4 | - | - | - | - |
| Other pharmaceuticals | 536 | 495 | 475 | 467 | -26% | -23% | -22% | -18% |
| Other revenue | 56 | 58 | 54 | 208 | -2% | -14% | -4% | 294% |

* Old antipsychotics, antidepressants, incl. citalopram




Cost, 5 year figures

| | DKK million | | | | | Growth, Y/Y, % | | | |
|-----------------------|-------------|-------|-------|-------|-------|----------------|------|------|------|
| | 2002 | 2003 | 2004 | 2005 | 2006 | 2003 | 2004 | 2005 | 2006 |
| Revenue | 9,488 | 9,941 | 9,733 | 9,070 | 9,221 | 5% | -2% | -7% | 2% |
| Production costs | 1,818 | 1,758 | 1,725 | 1,488 | 1,646 | -3% | -2% | -14% | 11% |
| Distribution costs | 2,458 | 2,478 | 2,302 | 2,337 | 2,419 | 1% | -7% | 2% | 4% |
| Administration | 1,323 | 1,612 | 1,364 | 1,303 | 1,419 | 22% | -15% | -5% | 9% |
| R&D | 1,575 | 1,931 | 1,776 | 1,782 | 1,958 | 23% | -8% | 0% | 10% |
| Other oper. exp., net | (31) | 15 | 12 | (8) | (4) | -- | -- | -- | -- |
| EBIT | 2,345 | 2,147 | 2,554 | 2,170 | 1,784 | -8% | 19% | -15% | -18% |

Cost, quartely figures

| | DKK million | | | | Growth, Y/Y, % | | | |
|-----------------------|-------------|------------|------------|------------|----------------|------------|------------|------------|
| | Q1 2006 | Q2 2006 | Q3 2006 | Q4 2006 | Q1 2006 | Q2 2006 | Q3 2006 | Q4 2006 |
| Revenue | 2,232 | 2,198 | 2,248 | 2,543 | 1% | -4% | -1% | 10% |
| Production costs | 420 | 437 | 372 | 417 | 2% | 10% | -3% | 42% |
| Distribution costs | 588 | 646 | 500 | 685 | 14% | 1% | -8% | 8% |
| Administration | 319 | 358 | 322 | 419 | 6% | 14% | -4% | 18% |
| R&D | 455 | 488 | 420 | 596 | 26% | 15% | -8% | 11% |
| Other oper. exp., net | - | 1 | 4 | (9) | -- | -- | -- | -- |
| EBIT | 451 | 269 | 630 | 435 | -29% | -47% | 16% | -10% |


Lundbeck hedge the USD on a rolling basis up to 12 months ahead – 2007 USD hedge rate of 5.78



Note: 2003-2006 includes value of average hedging contracts realised in the period



Lundbeck recognition of income from Forest




* Hedging effect at bulk delivery recognised on P&L: Gain/loss from difference in delivery at expected sales price at forward rate difference to spot rate at delivery



Cipralex® / Lexapro® - best-in-class antidepressant

| | Comparator | Presented | Main outcome |
|--------------------|------------------------------|---|--|
| Depression | Venlafaxine XR (Effexor) | SCNP, April 2003 | Escitalopram was at least as effective and was better tolerated than venlafaxine XR. Escitalopram treated patients reached sustained response and remission significantly faster. |
| | Venlafaxine XR (Effexor) | ECNP, September 2003 | Escitalopram was at least as effective and better tolerated than venlafaxine XR. Escitalopram was significantly more effective than venlafaxine XR in treating severely depressed patients. |
| | Sertraline (Zoloft) | ACNP, December 2003 | The starting dose of escitalopram was comparable efficacious to optimally dosed sertraline. |
| | Citalopram (Celexa/Cipramil) | International Clinical Psychopharmacology, April 2005 | Escitalopram was significantly more efficacious than citalopram. |
| | Paroxetine (Paxil) | IADC, February 2006 | Escitalopram was significantly more effective than paroxetine in the 24-week treatment of patients with severe MDD. |
| | Duloxetine (Cymbalta) | ACNP, December 2006 | Escitalopram was better tolerated and at least as effective as duloxetine in the treatment of MDD. |
| Anxiety | Comparator | Presented | Main outcome |
| | Paroxetine (Paxil) | SCNP, April 2003 | Escitalopram was significantly superior to paroxetine after 24 weeks of treatment of SAD and showed fewer discontinuation effects. |
| | Paroxetine (Paxil) | ACNP, December 2003 | Escitalopram was as effective as paroxetine in the long-term treatment of GAD and was better tolerated. |
| Paroxetine (Paxil) | ECNP, October 2004 | Escitalopram was superior to paroxetine for the change from baseline to Week 12 in the treatment of GAD and showed fewer discontinuation effects. | |

Global IP position



USA

Escitalopram: Compound patent to March 2012 (incl. extension)

Gaboxadol: Use patent to March 2016, excl. extensions

Sertindole: Use patent to April 2010, excl. extensions

International Markets

Bifeprunox: Compound patent in major markets to Feb. 2022

Escitalopram: Compound patent in major markets to 2009, excl. extensions

Gaboxadol: Use patent in major markets to July 2016, excl. extensions

Memantine: Use patent to April 2010

Rasagiline: Compound patent to 2011, excl. extensions

Sertindole: Use patent in major markets to March/April 2010, excl. extensions

Europe

Bifeprunox: Compound patent in majority of countries to Feb. 2022

Escitalopram: Compound patent in majority of countries to May-June 2014. Process patent in majority of countries to June 2014

Gaboxadol: Use patent in majority of countries to July 2021

Memantine: Data exclusivity until 2012. Use patent in major countries to April 2014


Rasagiline: Compound patent to 2011, excl. possibility of 5 year extension

Sertindole: Compound patent in majority of countries to March 2011



Worldwide pharmaceutical market 2005

USD 568,4 billion*, (+7%)



Source: IMS World Review 2006


Growth rates in local currency dollar 2004-2005 added in brackets

* Sales including estimates of non IMS audited panels = 601,4 billion



Worldwide CNS market 2005



USD 93,8 billion, (+5%)



Source: IMS World Review 2006
 Growth rates in local currency dollar 2004-2005 added in brackets



Alzheimer's (N7D-2005) – 4,0 bill. USD (+19%)





| Leading product | Marketing Corporation | Sales 2005 (USDm) | Growth in % |
|-----------------|-----------------------|-------------------|-------------|
| Aricept® | Eisai | 2.195 | 14 |
| Exelon® | Novartis | 492 | 7 |
| Reminyl® | Johnson & Johnson | 489 | 12 |
| Namenda® | Forest | 482 | 77 |
| Ebixa® | Lundbeck | 187 | 53 |

Source: IMS World Review 2006 (Knowledge link)

*) Not including hospital sales, which account for approximately 10% of sales of anti-Alzheimer's drugs




Depression (N6A-2005) – 19,9 bill. USD (-4%)



Source: IMS Health, December 2006, retail only.

| Leading product | Marketing Corporation | Sales 2005 (USDm) | Growth in % |
|---------------------|-----------------------|-------------------|-------------|
| Effexor® | Wyeth | 3.841 | 2 |
| Zoloft® | Pfizer | 3.651 | -3 |
| Lexapro®/Cipralextm | Lundbeck/Forest | 2.449 | 26 |
| Wellbutrin® | GlaxoSmithKline | 1.612 | -4 |
| Seroxtm/Paxiltm | GlaxoSmithKline | 1.227 | -37 |
| Yentreve® | Lilly | 686 | 769 |
| Prozac® | Lilly | 429 | -18 |
| Remeron® | Akzo Nobel | 361 | -25 |



Anti-Parkinson's (N4A - 2005) – 2,8 bill. USD (+10%)



Source: IMS World Review 2006

Source: IMS Health, December 2006, retail.



Antipsychotics (N5A-2005) – 16,3 bill. USD (+11%)



Source: IMS Health, December 2006, retail

| Leading product | Marketing Corporation | Sales 2005 (USDm) | Growth in % |
|-----------------|-----------------------|-------------------|-------------|
| Zyprexa® | Eli Lilly | 4.730 | -6 |
| Risperdal® | Johnson & Johnson | 4.055 | 13 |
| Seroquel® | AstraZeneca | 3.310 | 28 |
| Abilify® | Otsuka/BMS | 1.650 | 59 |
| Zeldox® | Pfizer | 731 | 26 |
| Leponex® | Novartis | 252 | -22 |
| Solian® | Sanofi-Synthelabo | 206 | -7 |

Hypnotics (N5B - 2005) – 4,6 bill. USD (+19%)




Source: IMS Health, December 2006, retail

| Leading product | Marketing Corporation | Sales 2005 (USDm) | Growth in % |
|-----------------|-----------------------|-------------------|-------------|
| Stilnox® | Sanofi-Synthelabo | 2.490 | 15 |
| Lunesta® | Sepracor | 311 | N/A |
| Lendormin® | Boehringer Ingelheim | 125 | 0 |
| Sonata® | Wyeth | 118 | -4 |
| Halcion® | Pfizer | 97 | -1 |
| Imovane® | Aventis | 80 | -1 |

Source: IMS World Review 2006 (IMS Knowledge link)

Alcohol (N7E - 2005) – USDm 112 (+26%)



Stroke, Fibrinolytics (B1D - 2005) – USDm 661 (+1%)

